On the alleged anticancer efficacy of the phosphoethanolamine pill, weakness of scientific evidence and ethical concerns
DOI:
https://doi.org/10.22239/2317-269X.00822Keywords:
Preclinical Studies, Clinical Research Ethics, Anticancer Drug, Oncologic Drugs, CancerAbstract
Anecdotal reports say that cancer patients improved after taking “synthetic phosphoethanolamine” (syn-PEA), anticancer pills produced and distributed by chemists from a Brazilian university. Notwithstanding the fact that syn-PEA pill inventors disseminated in the lay press the information that their drug is effective against different types of malignant tumors, they showed no clinical documentation or case reports to corroborate this statement. Moreover, syn-PEA failed to exhibit a consistent anticancer response in in vitro assays with human and murine cancer cell lines, and in in vivo xenograft tumor rodent assays. Despite the lack of nonclinical and clinical evidence of drug efficacy and safety, a bill authorizing production, prescription and consumption of syn-PEA pill passed the Congress and the president signed it into law (Law 13269/2016) on April 13, 2016. Astonishingly, the National Committee for Ethics in Research approved (April 19, 2016) syn-PEA trials in cancer patients in the absence of scientifically valid indications of a probable efficacy and without an adequate preclinical safety evaluation. It is unlikely that syn-PEA will eventually play a role in cancer therapy. Nonetheless, syn-PEA sad story unavoidably damaged country’s reputation as far as drug regulation and human research ethical standards are concerned.Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Health Surveillance under Debate: Society, Science & Technology (Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnología) – “Visa em Debate”
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT ALLOWANCE The author (s) hereinafter designated as the ASSIGNOR hereby assign and transfer, free of charge, the ownership of the copyrights related to this ARTICLE to the Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debate, represented by FUNDAÇÃO OSWALDO CRUZ, established at Av. Brasil, nº 4365, Manguinhos, Rio de Janeiro, RJ, Brazil, CEP 21045-900, under the conditions set out below: (a) The terms and conditions set forth in this Agreement shall apply to the following: 1. The ASSIGNOR declares that they s(he) is (are) the author (s) and owner (s) of the copyrighted property of the ARTICLE submitted. 2. The ASSIGNOR declares that the ARTICLE does not infringe the copyrights and / or other property rights of third parties, that the disclosure of images (if any) has been authorized and that they s(he) assume(s) full moral and / or property liability for its content, before third parties. 3. THE ASSIGNOR assigns and transfers all copyrights relating to the ARTICLE to the ASSIGNEE, especially the rights of editing, publication, translation into another language and reproduction by any process or technique. The ASSIGNEE becomes the exclusive owner of the rights related to the ARTICLE, and any reproduction, totally or partially, is prohibited in any other means of publicity, printed or electronic, without prior written authorization from the ASSIGNEE. 4. The assignment is free and, therefore, there will be no remuneration for the use of the ARTICLE by the ASSIGNEE.
